Eramet (ERA) Investor update summary
Event summary combining transcript, slides, and related documents.
Investor update summary
14 Oct, 2026Capital increase and funding plan
€500m rights issue planned for Q4 2026 to strengthen equity and the balance sheet, support near-term financing needs and maintain bank-covenant compliance.
Three-pillar funding plan combines the capital increase with a performance improvement plan, including ReSolution, and strategic asset monetization to support a return to medium-term growth.
2025 losses drove higher net debt, adjusted leverage of 5.5x and gearing of 125%, with bank-covenant breaches; operating performance improved in H1 2026.
Dividends will resume only when adjusted leverage falls below 1.0x; deleveraging is targeted well before 2030.
Asset disposals remain on track, with management avoiding fire sales; signing may occur this year and closing is expected next year.
Transaction structure and ownership
All shareholders receive preferential subscription rights pro rata; APE will subscribe for its 27.1% share and may buy all or part of Sorame-CEIR’s rights at a 5% discount to theoretical value.
The French State is expected to subscribe for 64% of the increase, including family rights; banks are expected to underwrite the remaining market portion.
If APE does not buy all Sorame-CEIR rights, Sorame-CEIR may subscribe for the balance; put and call options could transfer shares later, subject to regulatory approvals.
APE’s effective voting rights are capped below 49%; the French State is to remain below 50% of share capital, and an AMF waiver is required for crossing the 30% threshold.
APE is expected to become the largest shareholder and Sorame-CEIR the second-largest; a new shareholder agreement includes liquidity protections against excessive selling.
Timing and capital allocation
Completion is targeted after Q3 2026 turnover, scheduled for 29 October, and before year-end; timing depends on market conditions and an AMF waiver.
Process includes AMF prospectus approval, execution and targeted settlement; preparatory work and formation of a banking syndicate are planned.
Failure to complete by mid-2027 could weaken financial flexibility, bank-covenant compliance and refinancing of short-term debt maturities.
Argentina final investment decision is expected next year; if positive, related capex would occur in 2028–2030. Centenario debottlenecking’s first step is $350m.
Latest events from Eramet
- Manganese and lithium momentum meets a €500m funding drive amid uneven markets.ERA
Q3 2026 TU - EBITDA up 45%, funding plan on track, Senegal fire led to €112m impairment.ERA
H1 2026 - A pivotal year with a major funding plan, suspended dividends, and leadership transition.ERA
AGM 2026 - Q1 2026 turnover up 13% to €840m, with strong metals output and robust funding actions.ERA
Q1 2026 TU - Earnings and cash flow plunged in 2025, triggering a major recovery and funding plan for 2026.ERA
H2 2025 - Performance program targets EUR 130–170m EBITDA uplift and EUR 60–70m FCF boost in 2025.ERA
Status Update - EBITDA dropped 45% in H1 2025, with negative net income and rising debt amid market headwinds.ERA
H1 2025 - Lithium asset buyout, Q3 sales down 17%, CapEx cut, record mineral sands output, project suspensions.ERA
Q3 2024 TU - H1 2024 saw robust production growth but lower prices drove a net loss; H2 outlook is much stronger.ERA
H1 2024